Lipocine (LPCN) Stock Price, News & Analysis

Company Overview

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Key Stats

• Today's Range: $3.12 to $3.29
• 50-Day Range: $3.00 to $3.58
• 52-Week Range: $2.68 to $6.17
• Volume: 21,567 shs
• Average Volume: 36,252 shs
• Market Capitalization: $16.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Lipocine Stock Analysis - MarketRank™

Lipocine scored higher than 52% of companies evaluated by MarketBeat, and ranked 481st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lipocine has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lipocine has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lipocine is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lipocine is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lipocine has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.93% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently decreased by 10.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipocine does not currently pay a dividend.

Dividend Growth

Lipocine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.93% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently decreased by 10.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lipocine insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.35% of the stock of Lipocine is held by insiders.

Percentage Held by Institutions

Only 9.11% of the stock of Lipocine is held by institutions.

LPCN Stock Analysis - Frequently Asked Questions

How have LPCN shares performed this year?

Lipocine's stock was trading at $4.88 at the beginning of 2025. Since then, LPCN shares have decreased by 35.5% and is now trading at $3.15.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings results on Thursday, May, 8th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). The specialty pharmaceutical company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.35 million.

When did Lipocine's stock split?

Lipocine's stock reverse split on Friday, May 12th 2023.The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lipocine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipocine investors own include Zomedica (ZOM), Plug Power (PLUG), Workhorse Group (WKHS), Ovid Therapeutics (OVID), FuelCell Energy (FCEL), Fortress Biotech (FBIO) and KALA BIO (KALA).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LPCN
• CIK: 1535955
• Web: www.lipocine.com
• Phone: (801) 994-7383
• Fax: 801-994-7388
• Employees: 10
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Lipocine: $9.00
• High Price Target: $10.00
• Low Price Target: $8.00
• Potential Upside/Downside: +185.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $10 thousand
• Net Margins: N/A
• Pretax Margin: -146.12%
• Return on Equity: -26.68%
• Return on Assets: -24.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.64
• Quick Ratio: 15.64

Sales & Book Value

• Annual Sales: $11.20 million
• Price / Sales: 1.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.93 per share
• Price / Book: 0.80

Miscellaneous

• Outstanding Shares: 5,350,000
• Free Float: 5,010,000
• Market Cap: $16.85 million
• Optionable: No Data
• Beta: 1.24